BioAlliance Pharma Presents Results for Its New Oral Chemotherapy Nanoparticle Innovation at the AAPS Annual Meeting in Los Angeles, November 8 to 12, 2009

PARIS--(Business Wire)--
Regulatory News:

BioAlliance Pharma SA (Euronext Paris: BIO), a company dedicated to the
treatment and supportive care of cancer and AIDS patients, has presented its
results on new oral chemotherapy nanoparticle formulation at the AAPS (American
Association of Pharmaceutical Scientists) Annual Meeting in Los Angeles
(November 8 to 12, 2009).

Oral chemotherapy is a great challenge and its success is expected to make a
major breakthrough in cancer chemotherapy in the following years.

BioAlliance Pharma is developing an innovative proprietary nanoparticle
technology offering new therapeutic solutions for oral administration in
oncology. Using Sustained Release Nanoparticles (SRN) formulation, oral
chemotherapy can maintain optimum drug plasma concentrations, providing
prolonged exposure to cancer cells, then improving the efficacy and tolerance.

The data presented at the AAPS Meeting showed that the new oral formulation of
irinotecan (IRN-SRN) entrapped into nanoparticles, allowing an oral delivery of
IRN, significantly prolonged plasmatic half lives of IRN and SN-38, its active
metabolite, compared to those observed after the intravenous administration of
IRN, then increasing exposure to the active drug.

The IRN-SRN formulation tested in vivo in models of colorectal tumours was
demonstrated to have similar efficacy on tumour growth inhibition and to be
better tolerated than IRN administered IV.

"This oral nanoparticle innovation opens new ways to chemotherapy agents in
cancer treatments," commented Dominique Costantini, President and CEO,
BioAlliance Pharma.

About the American Association of Pharmaceutical Scientists (AAPS)

The purpose of AAPS is to serve its membership, the pharmaceutical sciences, the
biomedical and biotechnological community, the health professions, and the
interest of public health. This is accomplished by providing open forums for the
exchange and dissemination of scientific knowledge; by fostering the education
and career growth of members and recognizing individual achievement; by
influencing the formation of public policy relevant to health and related issues
of public concern; and, by promoting the pharmaceutical sciences as they relate
to health issues of public concern. Through its Annual Meeting, its conferences,
workshops and symposia, through its print and online publications and other
on-line initiatives, AAPS continues to offer vital benefits to the
pharmaceutical scientists who constitute its membership.

Recognizing that modern science is conducted in an integrated fashion comprising
many disciplines, AAPS seeks to foster the integration of those sciences related
to discovery, design, analysis, development, production, quality control,
safety, clinical evaluation, regulation, distribution and utilization of drugs
and drug delivery systems. Thus, AAPS should serve as the primary focus and
forum for interest in these disciplines.

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a
company which develops and markets innovative products in France, especially in
the fields of opportunistic infections and chemotherapy complications. In areas
where medical needs are insufficiently met, our targeted approaches help
overcome drug resistance and improve patient health & quality of life.
BioAlliance Pharma`s ambition is to become a leading player in these fields by
coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at
http://www.bioalliancepharma.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning BioAlliance Pharma SA and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors, which
could cause the actual results, financial condition, performance or achievements
of BioAlliance Pharma SA to be materially different from any future results,
performance or achievements expressed or implied by such forward-looking
statements. BioAlliance Pharma SA is providing this communication as of this
date and does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results,
financial condition, performance or achievements of BioAlliance Pharma SA to
differ from those contained in the forward-looking statements, please refer to
the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document
filed with the AMF on April 7, 2009, which is available on the AMF website
(http://www.amf-france.org) or on BioAlliance Pharma S.A.'s website
(http://www.bioalliancepharma.com).

BioAlliance Pharma SA
Dominique Costantini, +33-1-4558-7601
President and CEO
dominique.costantini@bioalliancepharma.com
or
Nicolas Fellmann, +33-1-4558-7100
CFO
nicolas.fellmann@bioalliancepharma.com
or
ALIZE RP
Caroline Carmagnol, +33-6-6418-9959
caroline@alizerp.com

Copyright Business Wire 2009